Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson’s Disease

Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease worldwide, affecting more than four million people. Typically, it affects individuals above 45, when they are still productive, compromising both aging and quality of life. Therefore, the cost of the disease must be iden...

Full description

Bibliographic Details
Main Authors: Tânia M. Bovolenta, Sônia Maria Cesar de Azevedo Silva, Roberta Arb Saba, Vanderci Borges, Henrique Ballalai Ferraz, Andre C. Felicio
Format: Article
Language:English
Published: Hindawi Limited 2017-01-01
Series:Parkinson's Disease
Online Access:http://dx.doi.org/10.1155/2017/3410946
id doaj-cd0156f238434dfba19a68ea683c6740
record_format Article
spelling doaj-cd0156f238434dfba19a68ea683c67402020-11-24T20:46:40ZengHindawi LimitedParkinson's Disease2090-80832042-00802017-01-01201710.1155/2017/34109463410946Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson’s DiseaseTânia M. Bovolenta0Sônia Maria Cesar de Azevedo Silva1Roberta Arb Saba2Vanderci Borges3Henrique Ballalai Ferraz4Andre C. Felicio5Programa de Pós-Graduação, Hospital Israelita Albert Einstein, São Paulo, SP, BrazilMovement Disorders Department in Neurology, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, BrazilUniversidade Federal de São Paulo (UNIFESP), São Paulo, SP, BrazilUniversidade Federal de São Paulo (UNIFESP), São Paulo, SP, BrazilUniversidade Federal de São Paulo (UNIFESP), São Paulo, SP, BrazilNeurology Program, Hospital Israelita Albert Einstein, São Paulo, SP, BrazilParkinson’s disease (PD) is the second most prevalent neurodegenerative disease worldwide, affecting more than four million people. Typically, it affects individuals above 45, when they are still productive, compromising both aging and quality of life. Therefore, the cost of the disease must be identified, so that the use of resources can be rational and efficient. Additionally, in Brazil, there is a lack of research on the costs of neurodegenerative diseases, such as PD, a gap addressed in this study. This systematic review critically addresses the various methodologies used in original research around the world in the last decade on the subject, showing that costs are hardly comparable. Nonetheless, the economic and social impacts are implicit, and important information for public health agents is provided.http://dx.doi.org/10.1155/2017/3410946
collection DOAJ
language English
format Article
sources DOAJ
author Tânia M. Bovolenta
Sônia Maria Cesar de Azevedo Silva
Roberta Arb Saba
Vanderci Borges
Henrique Ballalai Ferraz
Andre C. Felicio
spellingShingle Tânia M. Bovolenta
Sônia Maria Cesar de Azevedo Silva
Roberta Arb Saba
Vanderci Borges
Henrique Ballalai Ferraz
Andre C. Felicio
Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson’s Disease
Parkinson's Disease
author_facet Tânia M. Bovolenta
Sônia Maria Cesar de Azevedo Silva
Roberta Arb Saba
Vanderci Borges
Henrique Ballalai Ferraz
Andre C. Felicio
author_sort Tânia M. Bovolenta
title Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson’s Disease
title_short Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson’s Disease
title_full Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson’s Disease
title_fullStr Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson’s Disease
title_full_unstemmed Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson’s Disease
title_sort systematic review and critical analysis of cost studies associated with parkinson’s disease
publisher Hindawi Limited
series Parkinson's Disease
issn 2090-8083
2042-0080
publishDate 2017-01-01
description Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease worldwide, affecting more than four million people. Typically, it affects individuals above 45, when they are still productive, compromising both aging and quality of life. Therefore, the cost of the disease must be identified, so that the use of resources can be rational and efficient. Additionally, in Brazil, there is a lack of research on the costs of neurodegenerative diseases, such as PD, a gap addressed in this study. This systematic review critically addresses the various methodologies used in original research around the world in the last decade on the subject, showing that costs are hardly comparable. Nonetheless, the economic and social impacts are implicit, and important information for public health agents is provided.
url http://dx.doi.org/10.1155/2017/3410946
work_keys_str_mv AT taniambovolenta systematicreviewandcriticalanalysisofcoststudiesassociatedwithparkinsonsdisease
AT soniamariacesardeazevedosilva systematicreviewandcriticalanalysisofcoststudiesassociatedwithparkinsonsdisease
AT robertaarbsaba systematicreviewandcriticalanalysisofcoststudiesassociatedwithparkinsonsdisease
AT vanderciborges systematicreviewandcriticalanalysisofcoststudiesassociatedwithparkinsonsdisease
AT henriqueballalaiferraz systematicreviewandcriticalanalysisofcoststudiesassociatedwithparkinsonsdisease
AT andrecfelicio systematicreviewandcriticalanalysisofcoststudiesassociatedwithparkinsonsdisease
_version_ 1716811892804026368